Introduction {#s1}
============

In mammals, the stress-related peptide corticotropin-releasing factor (CRF) and its paralogs urocortins 1, 2, and 3 (Ucn 1, Ucn 2, Ucn 3), activate two CRF receptor subtypes, CRF~1~ and CRF~2~, to varying degrees [@pone.0063942-Fekete1]. CRF~1~ receptors mediate endocrine, behavioral, and autonomic responses to stress, which has spurred the development of drug-like CRF~1~ antagonists [@pone.0063942-Zorrilla1]. In contrast, the role of brain CRF~2~ receptors in stress responses remains controversial. Studies have implicated anti-stress-like actions, pro-stress-like actions, or a lack of involvement of CRF~2~ receptors [@pone.0063942-Fekete1]. Part of this uncertainty may reflect that, unlike the case with CRF~1~ antagonists [@pone.0063942-Zorrilla1], highly selective (\>10,000-fold selectivity), small molecule CRF~2~ antagonists remain unavailable. Researchers have instead used truncated CRF~2~-preferring (100--1000-fold selectivity) peptide fragments as CRF~2~ antagonists, principally \[D-Phe^11^,His^12^\]sauvagine(11--40)NH~2~ (antisauvagine-30; [@pone.0063942-Ruhmann1] and cyclo(31--34)\[D-Phe^11^,His^12^,CαMeLeu^13,39^,Nle^17^,Glu^31^,Lys^34^\]Ac-sauvagine~(8--40)~ (astressin~2~-B; [@pone.0063942-Rivier1]).

Antisauvagine-30 has been described as a selective CRF~2~ antagonist in the literature (1530 hits in Google Scholar as of August 2012). Antisauvagine-30 potently displaces radioiodinated CRF-related ligands from HEK293 cell membranes expressing recombinant mCRF~2b~ (*K~d~* = 1.4 nM; [@pone.0063942-Ruhmann1], hCRF~2a~ (*K~i~* = 0.8 nM; [@pone.0063942-Higelin1], or mCRF~2b~ receptors (*K~i~* = 0.41 nM; [@pone.0063942-Brauns1] and has lower affinity for HEK293 membranes expressing CRF~1~ receptors. Several findings suggest, however, that antisauvagine-30 may block CRF~1~ receptors at doses that have been used *in vivo*. First, antisauvagine-30 can displace \[^125^I\]-oCRF from HEK293-rCRF~1~ membranes (*Ki* = 154--166 nM; [@pone.0063942-Ruhmann1], [@pone.0063942-Brauns1] and \[^125^I\]-sauvagine from HEK293-hCRF~1~ membranes (*Ki* = 100 nM; [@pone.0063942-Hoare1]). Similarly, antisauvagine-30 competes with \[^125^I\]-astressin to bind rat and human uncoupled CRF~1~ receptors (*Ki* = 66 and 170 nM; [@pone.0063942-Hoare1], [@pone.0063942-Hoare2]. Yet, many intracerebroventricular and intracerebral studies have infused antisauvagine-30 at ∼4 orders greater concentrations (1--2 mM) (e.g., see [Table 1](#pone-0063942-t001){ref-type="table"}). Moreover, in its original characterization, antisauvagine-30 showed ∼30% of the rCRF~1~ antagonist potency of astressin [@pone.0063942-Ruhmann1], a potent CRF~1~ antagonist. Accordingly, antisauvagine-30 blocks oCRF-induced cAMP accumulation in HEK293-rCRF1 cells [@pone.0063942-Brauns2] and oCRF-induced cAMP responses in human retinoblastoma Y79 cells [@pone.0063942-Gutknecht1] with *IC~50s~* = 1--2 µM, concentrations 3 orders lower than those that have been injected. The incomplete selectivity of antisauvagine-30 raises concern that some putative anxiolytic/anti-stress-like actions of antisauvagine-30 previously attributed to antagonism of brain CRF~2~ receptors may involve a non-CRF~2~ target, such as CRF~1~ receptors.

10.1371/journal.pone.0063942.t001

###### Intracerebroventricular (ICV) studies of antisauvagine-30 effects on stress- or anxiety-related endpoints.

![](pone.0063942.t001){#pone-0063942-t001-1}

  Reference                           Minimum effective ICV injection   Concentration (µM)   Dose (nmol)                                  Result
  ---------------------------------- --------------------------------- -------------------- ------------- ----------------------------------------------------------------------
  [@pone.0063942-Kishimoto1]                   400 ng/0.5 µl                   219              0.11                         INCREASED anxiety-like behavior
  [@pone.0063942-Takahashi1]                   1--5 µg/2 µl                  140--680        ∼0.27--1.37                      Reduced anxiety-like behavior
  [@pone.0063942-Pelleymounter1]             1--10 nmol/2.5 µl              400--4000           1--10             Reduced CRF-induced anxiety-like behavior and anorexia
  [@pone.0063942-Miragaya1]                    2.2 nmol/2 µl                   1100              2.2                        Reduced stress-induced weight loss
  [@pone.0063942-Sutherland1]                   10 µg/5 µl                     550               2.7        Reduced stress-induced deficits in prepulse inhibition of startle
  [@pone.0063942-Chance1]                       10 µg/2 µl                     1370              2.7                       Reduced burn-induced hypermetabolism
  [@pone.0063942-Staub1]                        10 µg/2 µl                     1370              2.7                      Reduced Ucn 2-induced neuroactivation
  [@pone.0063942-Risbrough1]                    3 nmol/5 µl                    600                3            Reduced CRF-induced startle and prepulse inhibition deficits
  [@pone.0063942-Risbrough2]                    3 nmol/5 µl                    600                3                            Reduced CRF-induced startle
  [@pone.0063942-Pelleymounter2]                3 nmol/5 µl                    600                3                           Reduced anxiety-like behavior
  [@pone.0063942-Takahashi2]                    20 µg/5 µl                     1100              5.5                 Reduced CRF- and stress-induced neuroactivation
  [@pone.0063942-Sekino1]                       20 µg/5 µl                     1100              5.5                         Reduced stress-induced anorexia
  [@pone.0063942-Maruyama1]                     20 µg/5 µl                     1100              5.5              Reduced stress- and Ucn 2/Ucn 3-induced HPA-activation
  [@pone.0063942-NavarroZaragoza1]              20 µg/3 µl                     1800              5.5         Reduced somatic and noradrenergic responses to opiate withdrawal
  [@pone.0063942-Cooper1]                       20 µg/3 µl                     1800              5.5                    Reduced acquisition of conditioned defeat
  [@pone.0063942-Chen1]                        6 nmol/10 µl                    600                6        Reduced *des*-acyl ghrelin-induced changes in gastric motor activity
  [@pone.0063942-Cullen1]                    Osmotic minipump                  1200            30/day               Reduced CRF/Ucn 1-induced anorexia and weight loss

Note: Not only doses, but also concentrations, are listed because relative dilution of the injected concentration across a given volume of brain is what will determine the local concentration relevant to receptor pharmacodynamics. CRF = corticotropin-releasing factor, HPA = hypothalamic-pituitary-adrenal axis, Ucn = urocortin.

Many antibodies [@pone.0063942-Refojo1] and antagonists [@pone.0063942-DellaZuana1] were subsequently found to have off-target binding or activity when evaluated in knockout (KO) mice. Here, we tested the hypotheses that any potential anxiolytic-like actions of antisauvagine-30 would 1) be present in mice lacking functional CRF~2~ receptors, and 2) not be shared by the more selective CRF~2~ antagonist astressin~2~-B. Astressin~2~-B binds to CRF~2~ receptors *in vitro* with similar potency as does anti-sauvagine-30 (e.g., displacement of \[^125^I\]sauvagine from CHO-hCRF~2a~ membranes (*Ki* = 0.49 vs 0.29 nM), from intrinsic rCRF~2b~ in A7r5 cells (*Ki* = 0.17 vs 0.77 nM), and from CRF~2a~ in rat olfactory bulb (*Ki* = 0.50 vs 0.84 nM) [@pone.0063942-Hoare2]. But, astressin~2~-B shows one order less affinity for CRF~1~ receptors (*Ki*\>1000 nM and 890 nM, respectively) [@pone.0063942-Hoare1], [@pone.0063942-Hoare2] than does antisavuagine-30 (*Ki* = 100 nM) [@pone.0063942-Ruhmann1], [@pone.0063942-Brauns1], [@pone.0063942-Hoare1], [@pone.0063942-Hoare2].

A secondary goal of the present study was to evaluate the anxiety-related phenotype of CRF~2~ KO mice backcrossed to C57BL/6J background. Previous studies that reported an anxiogenic-like phenotype of CRF~2~ knockout mice were performed on a hybrid 129SvJ-C57BL/6J genetic background [@pone.0063942-Bale1], [@pone.0063942-Kishimoto1]. However, mixed genetic background transgenic mice can lead to spurious or inconsistent results due to the confounding (due to genetic linkage) and interactive influence of mixed genetic background on observed phenotypes [@pone.0063942-Gerlai1]. The CRF~2~ null mutation was introduced into embryonic stem cells of the 129Sv genetic background. Due to genetic linkage, CRF~2~ null mutant mice studied on a hybrid background will overrepresent the 129Sv genetic background as compared to wildtype mice, which will show comparatively more C57BL/6 background [@pone.0063942-Gerlai1]. Anxiogenic-like behavior is greater in 129Sv strain mice than in C57BL/6 mice, however [@pone.0063942-Contet1], [@pone.0063942-Voikar1], [@pone.0063942-Dockstader1], [@pone.0063942-Rodgers1]. As a result, it is not clear whether the previously reported anxiogenic-like CRF~2~ KO phenotype is actually due to the null mutation as opposed to linked 129Sv genetic material. Potentially consistent with the latter possibility, no anxiogenic-like phenotype in elevated plus-maze or open field behavior was seen in CRF~2~ KO mice backcrossed 3 generations (∼87.5%) to a C57BL/6J background (Coste et al., 2000). Therefore, we here revisit the anxiety-related phenotype of CRF~2~ KO mice that were previously reported to show anxiogenic-like behavior on a hybrid background [@pone.0063942-Bale1], but now studied after being backcrossed extensively (\>99.975%) onto a C57BL/6J background.

Materials and Methods {#s2}
=====================

Ethics Statement {#s2a}
----------------

Procedures adhered to the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH publication no. 85--23, 1996) and Principles of Laboratory Animal Care and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute (protocol \#08-0010). All surgery was performed under isoflurane anesthesia, and all efforts were made to minimize suffering.

Subjects {#s2b}
--------

Subjects were adult (26.5--32.3 g at study onset), male CRF~2~ receptor KO (*n* = 22; *Crhr2^tm1Klee^*/*Crhr2^tm1Klee^*; [@pone.0063942-Bale1] and wildtype littermate mice (*n* = 21; WT, ≥12 generations C57BL/6J backcrossing; ≥99.9755869% consomy) offspring of heterozygote breeding. Mice were group-housed under a reverse 12 h/12 h light/dark cycle in a humidity- (60%) and temperature-controlled (22°C) vivarium with chow (LM-485 Diet 7012, Harlan, Madison, WI) and water available *ad libitum*.

Surgery {#s2c}
-------

Anaesthetized (isoflurane, 1--3%) mice were stereotaxically (David Kopf, Tujunga, CA) implanted with a 27-gauge, 7.5 mm stainless steel guide cannula 1 mm above the lateral ventricle. Coordinates (in mm) were (anterior/posterior: −0.1, medial/lateral: ±1.0 from bregma, dorsal/ventral: −1.5 from skull; [@pone.0063942-Franklin1]. A 30-gauge obturator maintained patency. Mice recovered ≥7 days before testing. Cannula placement was inferred from successful gravity injection and from ventricular spread of injected dye in randomly tested mice.

Drugs and injection {#s2d}
-------------------

Antisauvagine-30 and astressin~2~-B were synthesized using solid-phase methodology, purified using HPLC and characterized using capillary zone electrophoresis, HPLC and MS [@pone.0063942-Rivier1]. Peptides were dissolved in 0.5× PBS before testing and kept on ice. For intracerebroventricular (i.c.v.) infusions, the 30-gauge injector extended 1 mm beyond the cannula and was attached to tubing (0.01 i.d., 0.03 o.d. inches) from which 2 µl solution was delivered into the ventricle by gravity over 30 sec. The injector was left in place for 60 sec. The pretreatment intervals, during which the mouse was returned to its home cage were 15 min for the marble burying test and 30 min for the plus-maze and shock-induced freezing tests.

Study design {#s2e}
------------

Mice were tested during the dark phase in the marble burying, elevated plus-maze, and shock-induced freezing tests using a between-subjects design for treatment. The same set of mice were subjects in the 3 tests. Experiments involved a 2 (Genotype: WT vs. KO)×3 (Antagonist: vehicle vs. antisauvagine-30 vs. astressin~2~-B) factorial design. The dose of antisauvagine-30 (i.c.v. ∼3 nmol, or 10.7 µg) was representative of doses used in previous studies of stress- or anxiety-related endpoints ([Table 1](#pone-0063942-t001){ref-type="table"}). Astressin~2~-B was administered at the same dose. Tests were spaced by one week, and mice received a given drug treatment no more than twice across the three tests.

Marble burying {#s2f}
--------------

For marble burying testing [@pone.0063942-Njunge1], mice were individually placed in a polycarbonate cage (29×18×12 cm) containing 20 marbles (1.5 cm diameter) evenly spaced on 5-cm deep bedding. Marbles covered at least two-thirds by bedding, an index of anxiogenic-like behavior, were counted 30 min later.

Elevated plus-maze {#s2g}
------------------

The plus-maze apparatus has four arms (5×30 cm) at right angles to each other, elevated 30 cm from the floor. Two arms have 16-cm black plastic walls (closed arms), and two arms have 16-cm clear plastic walls (more open arms). Controls tested in this modified apparatus spend 35--40% of their time on the open arms, allowing changes to be detected bidirectionally; mice tested in the original plus-maze (open arms with no wall) typically spend 10--15% of their time on the open arms, making it difficult to detect anxiogenic-like effects. Mice were placed on the center of the maze, and behavior was videorecorded for 5 min. Decreases in % open arm time, calculated as: 100\*open arm time/(open arm time+closed arm time) [@pone.0063942-File1], indicate increased anxiety-like behavior. More total arm entries indicate increased locomotor activity [@pone.0063942-File1].

Shock-induced freezing {#s2h}
----------------------

Mice were placed in a Mouse NIR Video Fear Conditioning System (Med Associates, St. Albans, VT) housed in a soundproofed box, allowed to habituate for 2 min and then exposed to three 1.5 mA, 1-sec footshocks, separated by 20 sec. Freezing, a CRF/CRF~1~-dependent defensive response [@pone.0063942-Kalin1], was measured automatically from real-time video recordings (30 frames per second) across 15 min using Video Fear Conditioning Software (Med Associates) that distinguishes between subtle movements, such as whisker twitches, tail flicks and freezing behavior.

Statistics {#s2i}
----------

Analysis of variance (ANOVA) was used to evaluate effects of Genotype, Antagonist and their interaction. Fisher\'s protected least significant difference tests identified pairwise differences. The software used was Systat 12.0 (SPSS, Chicago, IL).

Results {#s3}
=======

[Figure 1](#pone-0063942-g001){ref-type="fig"} shows that antisauvagine-30 reduced the duration of shock-induced freezing in both WT and CRF~2~ KO mice (Antagonist: *F* ~2,37~ = 4.17, *p*\<0.05). Antisauvagine-30-treated mice froze less than mice pretreated with either vehicle or astressin~2~-B (*p*s\<0.05), which did not differ from one another (*p* = 0.96). No Genotype (*F* ~1,37~ = 0.03, *p*\>0.85) or Genotype×Antagonist effects (*F* ~2,37~ = 0.39, *p*\>0.68) were seen.

![Effects of antisauvagine-30, astressin~2~-B and CRF~2~ genotype on shock-induced freezing.\
The data are expressed as *M* ± SEM. Antisauvagine-30 (i.c.v., 3 nmol) significantly and equally reduced the duration of shock-induced freezing in both wildtype and CRF~2~ knockout mice. In contrast, the same dose of astressin~2~B, a selective CRF~2~ antagonist, and CRF~2~ null genotype did not alter shock-induced freezing (*n* = 6--9/group). \**p*\<0.05, differs from vehicle and astressin~2~-B-treated mice (Fisher\'s protected least significant difference test).](pone.0063942.g001){#pone-0063942-g001}

[Table 2](#pone-0063942-t002){ref-type="table"} shows that there were no significant Genotype, Antagonist or Genotype×Antagonist effects on raw open arm time (*F* ~1,37~ = 1.07, *F* ~2,37~ = 1.22, *F* ~2,37~ = 2.41, all *p*s\>0.1), % open arm time calculated as a function of total arm time (*F* ~1,37~ = 1.12, *F* ~2,37~ = 1.16, *F* ~2,37~ = 2.13, all *p*s\>0.1), or the total number of arm entries in the elevated plus-maze (*F* ~1,37~ = 0.42, *F* ~2,37~ = 1.54, *F* ~2,37~ = 0.15, all *p*s\>0.2). There also were no significant Genotype (*F* ~1,37~ = 0.35, *p*\>0.55), Antagonist (*F* ~2,37~ = 0.12, *p*s\>0.89) or Genotype×Antagonist (*F* ~2,37~ = 1.52, *p*\>0.23) effects on the number of marbles buried in the marble burying test. *A priori* analysis in vehicle-treated mice considered separately also indicated no significant Genotype effect on shock-induced freezing (*p*\>0.15); plus maze measures of % open arm time (*p*\>0.15), open arm time (*p*\>0.14), or total arm entries (*p*\>0.72); or marbles buried (*p*\>0.24).

10.1371/journal.pone.0063942.t002

###### Effects of genotype and CRF antagonist on behavior in the elevated plus-maze and marble burying tests.

![](pone.0063942.t002){#pone-0063942-t002-2}

                           Vehicle    Antisauvagine-30   Astressin~2~-B                        
  ---------------------- ----------- ------------------ ---------------- ---------- ---------- -----------
  *Elevated plus-maze*                                                                         
  Open arm time, %        41.1±12.7       18.2±8.0          27.4±9.0      9.4±2.3    25.9±8.0   41.0±11.7
  Open arm time, sec       116±37          48±21             71±24          22±5      64±24      110±32
  Total arm entries       10.8±2.1        11.9±2.1          15.7±2.6      15.7±2.1   11.8±2.1   14.7±3.7
  *Marble burying*                                                                             
  Marbles buried           9.9±2.7        11.2±1.8          11.5±2.8      10.0±2.4   6.5±2.8    10.7±2.1

[The data are expressed as *M*+SEM. KO = knockout.]{.ul}

[Table 3](#pone-0063942-t003){ref-type="table"} lists published studies in which antisauvagine-30 was administered site-specifically to discrete brain regions as a CRF~2~ antagonist. As can be seen, the concentrations that have been infused locally range from 137--2000 µM, on the order of those given i.c.v. previously ([Table 1](#pone-0063942-t001){ref-type="table"}) and in the present study. The median concentration infused, 1050 µM is ∼3 orders greater than the reviewed *IC~50~* of antisavuagine-30 to block CRF~1~-mediated cAMP responses (∼1--2 µM) and ∼4 orders greater than reviewed binding constants (*K~d~*, *K~i~*∼0.066--0.166 µM) of antisauvagine-30 for CRF~1~ receptors.

10.1371/journal.pone.0063942.t003

###### Intracerebral (IC) site-specific studies of antisauvagine-30 effects on stress- or anxiety-related endpoints.

![](pone.0063942.t003){#pone-0063942-t003-3}

  Reference                       Minimum effective intracerebral injection   Dose (pmol)   Concentration (µM)                                     Result
  ------------------------------ ------------------------------------------- ------------- -------------------- -----------------------------------------------------------------------------
  [@pone.0063942-Lam1]                         0.25 µg/0.5 µl                    68.5              137                      Reduced alcohol-induced increases in dynorphin levels
  [@pone.0063942-Lam2]                         0.25 µg/0.5 µl                    68.5              137                     Reduced alcohol-induced increases in β-endorphin levels
  [@pone.0063942-Sananbenesi1]                  0.4 µg/0.5 µl                     110              220            Reduced stress-enhanced fear conditioning and Mek-1/2-dependent signaling
  [@pone.0063942-Radulovic1]                    0.4 µg/0.5 µl                     110              220             Reduced stress/CRF-induced anxiety-like behavior and cognitive deficits
  [@pone.0063942-Todorovic1]                    0.4 µg/0.5 µl                     110              220           Reduced stress-induced anxiety-like behavior and fear conditioning deficits
  [@pone.0063942-Sahuque1]                     0.2 nmol/0.5 µl                    200              400                 Reduced acquisition of a CRF-induced conditioned place aversion
  [@pone.0063942-Cooper2]                       0.5 µg/0.2 µl                     137              685                          Reduced the expression of conditioned defeat
  [@pone.0063942-Hammack1]                     0.5 nmol/0.5 µl                    500              1000                 Reduced inescapable shock-induced shuttlebox escape deficits
  [@pone.0063942-Turek1]                       55 pmol/0.05 µl                    55               1100                              Reduced ethanol-induced hypothermia
  [@pone.0063942-Bledsoe1]                       2 µg/0.5 µl                      550              1100                        Reduced isolation-induced anxiety-like behavior
  [@pone.0063942-Scholl1]                        2 µg/0.5 µl                      550              1100           Reduced CRF-induced CeA serotonin efflux in amphetamine pre-treated rats
  [@pone.0063942-Vuong1]                         2 µg/0.5 µl                      550              1100           Reduced heightened anxiety-like behavior in amphetamine pre-treated rats
  [@pone.0063942-Forster1]                       2 µg/0.5 µl                      550              1100                 Reduced CRF- or CeA-activation-induced mPFC serotonin efflux
  [@pone.0063942-Lukkes1]                        2 µg/0.5 µl                      550              1100                     Reduced CRF-induced increases in NAc serotonin efflux
  [@pone.0063942-Ohata2]                        1 nmol/0.5 µl                    1000              2000                                Reduced stress-induced anorexia
  [@pone.0063942-Amat1]                         1 nmol/0.5 µl                    1000              2000                Reduced Ucn 2-induced BLA serotonin efflux and neuroactivation.

Note: Not only doses, but also concentrations, are listed because relative dilution of the injected concentration across a given volume of brain is what will determine the local concentration relevant to receptor pharmacodynamics. Mek-1/2 = Mitogen-activated extracellular signal-regulated kinases; CeA = central nucleus of the amygdala; BLA = basolateral amygdala; mPFC = medial prefrontal cortex; NAc = nucleus accumbens; CRF = corticotropin-releasing factor; Ucn 2 = urocortin 2.

Discussion {#s4}
==========

The present study found that i.c.v. infusion of a dose of antisauvagine-30 intermediate to those used in the literature reduced shock-induced freezing in both wild-type and CRF~2~ KO mice, unlike the CRF~2~ antagonist astressin~2~-B, which did not mitigate shock-induced freezing in either genotype. The present study also found that neither CRF~2~ KO nor i.c.v. astressin~2~-B infusion produced anxiolytic-like effects in 3 tests of anxiety-like behavior. Altogether, the results indicate that increasing doses of antisauvagine-30 lose their specificity and can exert non-CRF~2~-mediated effects at doses previously used. The collective results do not support the hypothesis that activation of brain CRF~2~ receptors tonically promotes anxiogenic-like behavior.

Antagonism of CRF~1~ receptors is a plausible mechanism for the non-CRF~2~ mediated anxiolytic-like actions of antisauvagine-30 seen here on shock-induced freezing. The low-moderate CRF~1~ binding affinities (∼100 nM) of antisauvagine-30 are not shared by the other widely used CRF~2~ antagonist, astressin~2~-B (*K~i~*\>1000 nM and 890 nM, respectively; [@pone.0063942-Hoare1], [@pone.0063942-Hoare2], which is similarly potent to antisauvagine-30 at binding CRF~2~ receptors (e.g., displacement of \[^125^I\]sauvagine from CHO-hCRF~2a~ membranes \[*K~i~* = 0.49 vs. 0.29 nM\], from intrinsic rCRF~2b~ in A7r5 cells \[*K~i~* = 0.17 vs. 0.77 nM\], and from CRF~2a~ in rat olfactory bulb \[*K~i~* = 0.50 vs. 0.84 nM\]; [@pone.0063942-Hoare2]. Accordingly, the i.c.v. dose of astressin~2~-B used here, which can block anorexia induced by urocortin 3, a selective CRF~2~ agonist [@pone.0063942-Fekete2], did not reduce shock-induced freezing. The results suggest that astressin~2~-B is more CRF~2~-selective than antisauvagine-30.

Many previous studies using antisauvagine-30 have interpreted that its effects were not CRF~1~ mediated because central administration of small molecule, selective CRF~1~ antagonists did not produce the same effects. Unfortunately, these comparisons have involved excessively lipophilic CRF~1~ antagonists, such as NBI27914, CP-154,526, or antalarmin, which are water insoluble, precipitate upon central administration and may therefore not diffuse to target sites or be available for pharmacological activity. Better controls would involve less hydrophobic, recently developed CRF~1~ antagonists more suitable for intracerebral administration, such as NBI-35965, GW-876008, pexacerfont or BMS-561,388.

Neither CRF~2~ KO nor selective CRF~2~ antagonism via astressin~2~-B altered behavior in three anxiety models, suggesting that CRF~2~ signaling is not a key modulator of anxiety-like behavior under basal conditions. Two previous studies that reported a basal anxiogenic-like phenotype of CRF~2~ knockout mice were performed on a hybrid 129SvJ-C57BL/6J genetic background [@pone.0063942-Bale1], [@pone.0063942-Kishimoto1]. In contrast, similar to the present results in mice fully backcrossed onto a C57BL/6J background, no significant anxiety-like phenotype was seen in CRF~2~ knockout mice backcrossed 3 generations toward a C57BL/6J background [@pone.0063942-Coste1]. Thus, because 129Sv and C57BL/6J mice differ in anxiety-like behavior [@pone.0063942-Contet1], [@pone.0063942-Voikar1], [@pone.0063942-Dockstader1], [@pone.0063942-Rodgers1], genetic background may have interacted with the effect of CRF~2~ null mutation on behavioral measures in previous studies [@pone.0063942-Gerlai1]. However, these results should not be prematurely concluded to mean that CRF~2~ receptors do not modulate anxiety-like behavior. Consistent with an anxiolytic-like action of CRF~2~ activation, i.c.v. administration of type 2 urocortins, selective CRF~2~ agonists, can produce anxiolytic-like and anti-stress-like behavioral effects [@pone.0063942-Valdez1], [@pone.0063942-Valdez2], [@pone.0063942-Zorrilla2], [@pone.0063942-Zhao1], [@pone.0063942-Ohata1], [@pone.0063942-Venihaki1], [@pone.0063942-Telegdy1], [@pone.0063942-Tanaka1], [@pone.0063942-Tanaka2]. Perhaps CRF~2~ receptors are normally quiescent under basal conditions, but are recruited in compensatory opposition to high or more sustained stress, as brought out following stressors or the anxiogenic-like 129Sv genetic background. Consistent with this hypothesis, CRF~2~ KO mice previously showed an anxiogenic-like phenotype in the light-dark box test following 30-min immobilization stress, but not under basal conditions (see Fig. 6A in [@pone.0063942-Henry1]). Under this view, the stressful aspects of the 3 tests used in the present study (novelty, brief shock) may have been too brief in duration (\<5 min), mild in magnitude, or initiated too soon before the behavioral assessment to allow a putative compensatory CRF~2~ response to be observed. Finally, it cannot be ruled out that a larger sample size might have led to a statistically significant *p*-value. For example, a trend for an anxiogenic-like effect of CRF~2~ null mutation, as reported previously [@pone.0063942-Bale1], [@pone.0063942-Kishimoto1], was present in vehicle-treated subjects of the elevated plus-maze that, if considered separately, would have attained significance with a sample size of 16/group (standardized Cohen\'s *d* = −0.73).

While antisauvagine-30 exerted non-CRF~2~ actions at the tested dose, this does not mean that it is intrinsically non-selective. Lower *in vivo* doses or concentrations might be shown via a KO control study to be adequately selective for functional studies. Indeed, the finding that a low central dose of antisauvagine-30 (i.c.v., 400 ng) previously produced an anxiogenic-like effect, opposite to those seen with increasing doses of the antagonist (see [Table 1](#pone-0063942-t001){ref-type="table"}), is consistent with the interpretation that antisauvagine-30 may lose specificity with increasing doses. The present result with a 3 nmol dose of antisauvagine-30 suggests that many (if not most) previous intracranial administration studies used a dose that can exert non-CRF~2~ mediated effects, complicating their interpretation ([Table 1](#pone-0063942-t001){ref-type="table"}). Utilization of CRF~2~ antagonists at doses validated to be subtype-selective in knockout mice can help further clarify the biological significance of brain CRF~2~ systems in stress-related behavior.
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